Kiley Andreas
Psychiatric/Mental Health · Minot, NDNPI 1598072035
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $473 and has fallen 76.3% since, to $112 in 2025. Among psychiatric/mental health clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$315
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$259
- AbbVie$246
- Sunovion Pharmaceuticals Inc.$216
- Alkermes, Inc.$129
- Takeda Pharmaceuticals U.S.A., Inc.$104
- plus $287 from 9 others
What the payments were for
- Food & beverage$1,50797%
- Education$493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 18 | $315 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $259 |
| AbbVie(2 entities) | 17 | $246 |
| Sunovion Pharmaceuticals Inc. | 22 | $216 |
| Alkermes, Inc. | 8 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $104 |
| Otsuka America Pharmaceutical, Inc. | 5 | $78 |
| Merck | 4 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Orexo US, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
How this compares
$1,556 in reported general payments places this provider in the 90th percentile of 92 psychiatric/mental health providers in North Dakota.
See all psychiatric/mental health providers in North Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 14 | $17,638 |
| TrintellixVortioxetine Hydrobromide | 13 | $6,000 |
| Aripiprazole | 75 | $5,699 |
| Sertraline Hcl | 233 | $3,054 |
| Mirtazapine | 77 | $1,456 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 25 | $1,430 |
| Duloxetine Hcl | 66 | $1,242 |
| Gabapentin | 39 | $1,235 |
| Buspirone Hcl | 44 | $913 |
| Trazodone Hcl | 60 | $746 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $691 |
| Olanzapine | 35 | $612 |
| Bupropion XlBupropion Hcl | 17 | $563 |
| Fluoxetine Hcl | 32 | $504 |
| Bupropion Hcl SrBupropion Hcl | 12 | $469 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $78 | $17,63814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $104 | $6,00013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 psychiatric/mental health providers in North Dakota.
Other psychiatric/mental health in Minot
- Roxann BrownMinot$3K
- Tonya AndersonMinot$3K
- Jennifer WoiwodeMinot$2K
- Bobbie BusethMinot$2K
- Tammy UlebergMinot$2K
- Stacy FlatenMinot$987
- Pamela WallsMinot$823
- Melissa ScheppMinot$797
- Alicja CebulakMinot$661
- Amanda DaggettMinot$545
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.